Lupus Nephritis

Tubulointerstitial Nephritis

Hereditary Nephritis

IFNα-Kinoid

Lupus : A major unmet medical need Lupus is a chronic and severe autoimmune disease in which the immune system produces antibodies to cells within the body leading to widespread inflammation and t...

Acute tubulointerstitial nephritis ATIN

Lupus nephritis: Implications of the new ACR lupus nephritis guidelines

The American College of Rheumatology recently published guidelines for the screening, treatment, and management of lupus nephritis. How will or should these guidelines impact our current daily practic...

Connective tissue diseases: Management of lupus nephritis—new guidelines revealed

The past decade has seen exciting progress in the management of lupus nephritis, a manifestation of systemic lupus erythematosus that accounts for its major morbidity and mortality. The American Colle...

Lupus nephritis: Guidelines for lupus nephritis—more recommendations than data?

Several management guidelines for lupus nephritis have been published this year. All of the guidelines provide clear and consistent recommendations, but although evidence-based, many of the recommenda...

Lupus nephritis: Urinary CD4+ T cells—a marker of proliferative lupus nephritis

FDA withdraws lupus guidance

FDA withdrew 2010 guidance on the development of products to treat systemic lupus erythematosus (SLE) and lupus nephritis caused by SLE. The agency said in a notice that the guidance "no longer reflec...

Markers Reflect Kidney Changes in Lupus (CME/CE)

(MedPage Today) -- Combinations of urinary biomarkers reflect the renal tissue changes occurring in lupus nephritis and ultimately may be useful in noninvasive longitudinal disease assessment, researc...

B-cell depletion in the treatment of lupus nephritis

Lupus nephritis is the most common severe manifestation of the autoimmune disease systemic lupus erythematosus. Although conventional immunosuppressive therapy can increase survival, this approach is...

Lupus nephritis: Transatlantic management recommendations compared

In the wake of publication of clinical data for new drugs in the management of lupus nephritis, European rheumatology and renal societies have issued new recommendations for management of this conditi...

Biomarkers in lupus nephritis.

Systemic lupus erythematosus is a polysystemic autoimmune disease. One of the most common and serious complication is lupus nephritis. Notification of these complications before organic disorder, pred...

Correlations of Urinary Biomarkers, TNF-Like Weak Inducer of Apoptosis (TWEAK), Osteoprotegerin (OPG), Monocyte Chemoattractant Protein-1 (MCP-1), and IL-8 with Lupus Nephritis.

OBJECTIVE: This case-controlled study was designed to correlate urinary biomarkers, TNF-like weak inducer of apoptosis (TWEAK), osteoprotegerin (OPG), monocyte chemoattractant protein-1 (MCP-1), and i...

Biological therapy for lupus nephritis-tribulations and trials.

Several new targeted biologic agents for treating lupus nephritis are on the horizon; however, it is important to determine the circumstances in which they should be used, and how to optimally combine...

Recent advances in the treatment of lupus nephritis.

Lupus nephritis is a common complication of systemic lupus erythematosus (SLE) which is associated with significant morbidity and mortality. The concept of two phases of therapy for lupus nephritis, s...

Lupus nephritis: Urinary CD4(+) T cells-a marker of proliferative lupus nephritis.